Some identified specific molecular biomarkers associated with cervical cancer development (like HPV DNA, p16, Ki67, etc.)can provide improved accuracy and sensitivity of cervical cancer screening, predict the risk of progression to invasive cancer, predict treatment responses and enable treatment monitoring and predict survival outcomes [13]. This evidence concerns the gene MKI67 and cervical cancer.